SK生物科学开始在澳大利亚试验针对类似SARS病毒的通用冠状病毒疫苗。 SK bioscience begins Australian trial for universal coronavirus vaccine targeting SARS-like viruses.

SK生物科学公司在澳大利亚提交了第1/2阶段临床试验申请,申请511英镑,这是针对包括SARS-CoV-2和原SARS病毒在内的萨尔贝科病毒的通用冠状病毒疫苗。 SK bioscience has filed a Phase 1/2 clinical trial application in Australia for GBP511, a universal coronavirus vaccine targeting sarbecoviruses including SARS-CoV-2 and the original SARS virus. 审判将招收约500名健康成年人,以评估安全和跨反应性免疫反应,预计到2028年取得初步结果。 The trial will enroll about 500 healthy adults to evaluate safety and cross-reactive immune responses, with initial results expected by 2028. 自2021年以来,疫苗由CEPI供资6 500万美元,使用SK生物科学的重组蛋白质平台以及华盛顿大学的纳米粒子技术。 Funded by CEPI with $65 million since 2021, the vaccine uses SK bioscience’s recombinant protein platform and nanoparticle technology from the University of Washington. 世界卫生组织强调,由于不断的病毒演变和大流行病风险,需要使用广谱冠状病毒疫苗。 The World Health Organization has stressed the need for broad-spectrum coronavirus vaccines due to ongoing viral evolution and pandemic risks. 全球COVID-19疫苗市场预计到2032年将达到834亿美元。 The global COVID-19 vaccine market is projected to reach $83.4 billion by 2032. SK生物科学还正在推进其他大流行病应对方案,包括以MRNA为基础的日本脑炎疫苗和政府支持的禽流感倡议。 SK bioscience is also advancing other pandemic-response programs, including an mRNA-based Japanese encephalitis vaccine and a government-backed avian influenza initiative.